Journal article
The use of prognostic factors in metastatic renal cell carcinoma
Abstract
BACKGROUND: Over the last decade, the treatment landscape of metastatic renal cell carcinoma (mRCC) has evolved tremendously. The outcome of patients with mRCC has been improved since the advent of targeted therapy.
OBJECTIVE: In this review, we address the use of prognostic schema in the era of targeted treatment. This article summarizes the current available prognostic models and the evidence to support their use in clinical settings.
Authors
Li H; Samawi H; Heng DYC
Journal
Urologic Oncology Seminars and Original Investigations, Vol. 33, No. 12, pp. 509–516
Publisher
Elsevier
Publication Date
December 2015
DOI
10.1016/j.urolonc.2015.08.003
ISSN
1078-1439